Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
03. September 2024 17:14 ET
|
Royalty Pharma plc
NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma...
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
28. August 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley’s 22nd Annual Health Care Conference on...
Royalty Pharma Reports Second Quarter 2024 Results
08. August 2024 07:00 ET
|
Royalty Pharma plc
Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $658 millionRaising full year 2024 guidance: Portfolio Receipts expected to...
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
24. Juli 2024 08:30 ET
|
Royalty Pharma plc
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins...
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
19. Juli 2024 08:15 ET
|
Royalty Pharma plc
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the...
Royalty Pharma Declares Third Quarter 2024 Dividend
17. Juli 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A...
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
04. Juni 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global...
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
03. Juni 2024 17:15 ET
|
Royalty Pharma plc
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following...
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
28. Mai 2024 07:10 ET
|
Royalty Pharma plc
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented...
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
22. Mai 2024 16:10 ET
|
Royalty Pharma plc; Cytokinetics
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) --...